scholarly journals COVID-19 in a Patient with Chronic Lymphocytic Leukaemia with Pseudohypoxemia

2020 ◽  
Author(s):  
Orivaldo Alves Barbosa ◽  
Talita Guimarães Andrade ◽  
Maria Danielly de Almeida Sousa ◽  
José Walter Correia
Keyword(s):  
At Risk ◽  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Severe Infection ◽  
The Elderly ◽  
Immunocompromised Patients ◽  
Haematological Cancer ◽  
Elderly Hypertensive

Infection with SARS-CoV-2 causes critical disease in approximately 5% of affected patients, particularly the elderly, hypertensive, obese and immunocompromised. Patients with haematological cancer, including chronic lymphocytic leukaemia (CLL), are particularly at risk of complications. Very rarely, patients with extreme leukocytosis may develop spurious hypoxemia, or pseudohypoxemia, which confuses the diagnosis of complications and can lead to intervention errors. We report the case of a patient with CLL, severe infection with SARS-CoV-2 and pseudohypoxemia.

scholarly journals Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review

2017 ◽  
Vol 8 (6) ◽  
pp. 197-205 ◽  
Author(s):  
Othman Al-Sawaf ◽  
Paula Cramer ◽  
Valentin Goede ◽  
Michael Hallek ◽  
Natali Pflug
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
The Elderly ◽  
Current Data ◽  
Oral Medications ◽  
Therapeutic Decisions ◽  
Unfit Patients ◽  
Line Setting ◽  
New Compounds

With a median age of 72 years at first diagnosis, chronic lymphocytic leukaemia (CLL) is a disease of the elderly. At this age, many patients cannot bear an intensive chemoimmunotherapy like fludarabine, cyclophosphamide and rituximab (FCR), and therapeutic decisions are commonly complicated by a high burden of accompanying comorbidities. Clinical trials, on the other hand, are mostly designed to include a far healthier and younger trial population, with a median age in most studies well below 70 years, leading to an insufficient reflection of clinical reality. With the introduction of new targeted therapies, treatment of CLL is currently undergoing a profound change. New compounds like ibrutinib or idelalisib have enlarged the therapeutic options in treating CLL. However, so far, these oral medications imply continuous intake by the patient, which will at some point lead to the issue of adherence in most patients. In addition, long-term experiences are largely missing. In this setting, one of the oldest chemoactive substances remains a viable option for many CLL patients and their treating physicians: bendamustine, a nitrogen–mustard derivative, has proven to be a safe and efficient agent for treatment of CLL in the first- and second-line setting. In particular, there is some evidence that the substance is relatively well tolerated in elderly and unfit patients. In this review, we summarize the current data on bendamustine in the treatment of elderly and unfit patients with CLL and aim to provide a concise analysis and outlook on the current and future role of this substance in the era of new targeted agents.

scholarly journals High pot but no T

2020 ◽  
Vol 13 (3) ◽  
pp. 307-310
Author(s):  
Luis Miguel Manrique-Gonzalez ◽  
Berta Truttmann ◽  
Thomas Münzer MD
Keyword(s):  
At Risk ◽  
Cancer Patient ◽  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Test Results ◽  
Technical Factors ◽  
Patient At Risk ◽  
Leukemia In Children

Introduction. The identification and treatment of patients with hyperkalemia is necessary to prevent the development of arrhythmias. Pseudohyperkalemia is most commonly due to specimen haemolysis and is often recognised by laboratory scientists who subsequently report test results with cautionary warnings. The authors present a case of pseudohyperkalemia in a patient with chronic lymphocytic leukaemia. Report case: the technical factors and method of transport are a potential cause of pseudohyperkalemia. Pseudohyperkalemia has been associated with hyperleukoctosis, in cancer patient populations, more commonly in CLL in adults, but also acute lymphoblastics leukemia in children. This places the patient at risk of unnecessary and potentially dangerous treatments. Conclusion: Physicians should consider pseudohyperkalemia as the underlying cause of elevated potassium levels in patients with malignant leucocytosis who do not have signs or symptom of systemic hyperkalemia.

Refractory Bartonella quintana bacillary angiomatosis following chemotherapy for chronic lymphocytic leukaemia

2011 ◽  
Vol 60 (1) ◽  
pp. 142-146 ◽  
Author(s):  
Natasha E. Holmes ◽  
Stephen Opat ◽  
Anthony Kelman ◽  
Tony M. Korman
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Standard Treatment ◽  
Lymphocytic Leukaemia ◽  
Bartonella Henselae ◽  
Immunocompromised Patients ◽  
Bartonella Quintana ◽  
Bacillary Angiomatosis ◽  
Systemic Manifestations

Bacillary angiomatosis is a well-recognized infection with cutaneous and systemic manifestations caused by Bartonella henselae or Bartonella quintana and occurs in immunocompromised patients. We report a case of B. quintana bacillary angiomatosis following fludarabine-based chemotherapy for chronic lymphocytic leukaemia that was refractory to standard treatment and was complicated by lymphadenopathy and osteomyelitis.

scholarly journals Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

2021 ◽  
Vol 11 (7) ◽  
Author(s):  
H. Parry ◽  
G. McIlroy ◽  
R. Bruton ◽  
M. Ali ◽  
C. Stephens ◽  
...  
Keyword(s):  
Antibody Response ◽  
Chronic Lymphocytic Leukaemia ◽  
Specific Antibody ◽  
Lymphocytic Leukaemia ◽  
Vaccination Strategy ◽  
Severe Infection ◽  
Dried Blood Spots ◽  
Iga Deficiency ◽  
Antibody Responses ◽  
Healthy Donors

AbstractB-cell chronic lymphocytic leukaemia (CLL) is associated with immunosuppression and patients are at increased clinical risk following SARS-CoV-2 infection. Covid-19 vaccines offer the potential for protection against severe infection but relatively little is known regarding the profile of the antibody response following first or second vaccination. We studied spike-specific antibody responses following first and/or second Covid-19 vaccination in 299 patients with CLL compared with healthy donors. 286 patients underwent extended interval (10–12 week) vaccination. 154 patients received the BNT162b2 mRNA vaccine and 145 patients received ChAdOx1. Blood samples were taken either by venepuncture or as dried blood spots on filter paper. Spike-specific antibody responses were detectable in 34% of patients with CLL after one vaccine (n = 267) compared to 94% in healthy donors with antibody titres 104-fold lower in the patient group. Antibody responses increased to 75% after second vaccine (n = 55), compared to 100% in healthy donors, although titres remained lower. Multivariate analysis showed that current treatment with BTK inhibitors or IgA deficiency were independently associated with failure to generate an antibody response after the second vaccine. This work supports the need for optimisation of vaccination strategy in patients with CLL including the potential utility of booster vaccines.

scholarly journals Early stage chronic lymphocytic leukaemia carrying unmutated IGHV genes is at risk of recurrent infections during watch and wait

2008 ◽  
Vol 141 (5) ◽  
pp. 734-736 ◽  
Author(s):  
Davide Rossi ◽  
Lorenzo De Paoli ◽  
Francesca M. Rossi ◽  
Michaela Cerri ◽  
Clara Deambrogi ◽  
...  
Keyword(s):  
At Risk ◽  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Early Stage ◽  
Recurrent Infections ◽  
Watch And Wait

Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia

2000 ◽  
Vol 111 (1) ◽  
pp. 230-238 ◽  
Author(s):  
Mohammad Reza Rezvany ◽  
Mahmood Jeddi-Tehrani ◽  
Hodjattallah Rabbani ◽  
Ulla Ruden ◽  
Lennart Hammarstrom ◽  
...  
Keyword(s):  
T Lymphocytes ◽  
Chronic Lymphocytic Leukaemia ◽  
B Cell ◽  
Lymphocytic Leukaemia ◽  
Cell Chronic Lymphocytic Leukaemia ◽  
Cdr3 Region

Pharmacokinetics of Chlorambucil in Patients with Chronic Lymphocytic Leukaemia: Comparison of Different Days, Cycles and Doses

2000 ◽  
Vol 87 (5) ◽  
pp. 223-228 ◽  
Author(s):  
Raija Silvennoinen ◽  
Kimmo Malminiemi ◽  
Outi Malminiemi ◽  
Erkki Seppala ◽  
Juhani Vilpo
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia

The Local Sanarelli-Shwartzman Phenomenon in Rats Induced by Human Leukaemic Cells

1973 ◽  
Vol 29 (02) ◽  
pp. 353-362
Author(s):  
J Lisiewicz ◽  
A Pituch ◽  
J. A Litwin
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Intravenous Injection ◽  
Peripheral Blood ◽  
Lymphocytic Leukaemia ◽  
Acute Myeloblastic Leukaemia ◽  
Demarcation Line ◽  
E Coli ◽  
Leukaemic Cells ◽  
Shwartzman Phenomenon

SummaryThe local Sanarelli-Shwartzman phenomenon (SSP-L) in the skin of 30 rats was induced by an intr a cutaneous sensitizing injection of leukaemic leucocytes isolated from the peripheral blood of patients with chronic lymphocytic leukaemia (CLL), acute myeloblastic leukaemia (AL) and chronic granulocytic leukaemia (CGL) and challenged by an intravenous injection of 100(μ of E. coli endotoxin. SSP-L was observed in 7 rats after injection of CLL lymphocytes and in 6 and 2 rats after AL myeloblasts and the CGL granulocytes, respectively. The lesions in the skin after AL myeloblasts appeared in a shorter time and were of longer duration compared with those observed after CLL lymphocytes and CGL granulocytes. Histologically, the lesions consisted of areas of destruction in the superficial layers of the skin ; the demarcation line showed the presence of neutrophils, macrophages and erythrocytes. Haemorrhages and fibrin deposits near the demarcation line were larger after injection of CLL lymphocytes and AL myeloblasts than after CGL granulocytes. The possible role of leucocyte procoagulative substances in the differences observed have been discussed.

Sign in / Sign up

Export Citation Format

Share Document